随着制药行业转向越来越复杂的专业治疗，对于高度定义的，通常很少的患者人群，竞争加剧了，付款人的紧张局势越来越大。创新发射的回报并没有跟上临床开发成本上升的步伐。
制药行业既是最好的和最糟糕的时代。该行业正处于管道生产率的黄金时代 - 但是，随着重点转向更加精致的专业治疗，用于高度定义的，通常很少的患者人群，竞争加剧，付款人紧张局势也会增长。推动该行业大部分创新回报的国家 /地区都会看到预算挑战，回扣和折扣增长以及风险增加。
盈利能力降低了，创新发射的回报并没有跟上临床开发成本上升的步伐。随着生物制剂经历低成本竞争，投资组合会看到排他性后丧失后更快，更广泛的价值侵蚀。技术已大大提高了数据的可用性，以更好地了解患者和状况，以证明新药物的价值并指导制药决策。但是通常，公司努力使这些数据充分利用。
The pharmaceutical industry is in a revolutionary period of innovation. Advances in understanding the genomics of disease, and in the personalisation of treatment, have been augmented by the introduction of regenerative medicine platforms, where gene and cell therapies offer curative approaches to serious, often life limiting, disease. If these technologies fulfil their promise, they will revolutionise the pharmaceutical market far more fundamentally than the advent of biologic therapies in cancer and autoimmune disease in the 1990s and early 2000s. Disease areas will be transformed, and healthcare systems will need to re-design their approaches to provision of, and payment for treatments. The pharmaceutical companies making the right choices on the right assets have extraordinary commercial opportunities.
This white paper presents the case for revolutionizing research and development, and outlines new approaches to make clinical trials more cost effective and focused from start to finish.